| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 0.60 | 0.00 (-0.34%) | 0.43 - 1.62 | 92.8 thousand (Below Avg) |
Market data as of 12:18PM 05/23/13. Quotes are delayed by at least 15 min.
| Open | 0.60 |
|---|---|
| Previous Close | 0.60 |
| Day's Range | 0.58 - 0.61 |
| Market Cap | 75.7M |
| Avg Volume (10 Day) | 573.7K |
| Price/Earnings (Trailing 12 Mo.) | 4.4x |
| Earnings Per Share (Trailing 12 Mo.) | 0.3 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Zalicus Presents Data on Novel, Oral, N- and T-Type Calcium Channel Blockers for the Treatment of Pain
Business Wire - Friday 05/10/2013 8:45 AM ET
Zalicus Secures New $25 Million Funding Commitment from Lincoln Park Capital
Business Wire - Wednesday 05/08/2013 8:30 AM ET
Zalicus Reports Financial Results for the First Quarter 2013
Business Wire - Thursday 05/02/2013 7:30 AM ET
| ZLCS | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 50.59% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.62 | |
| LT Debt/Equity | 0.33 | |
| Earnings Yield | 22.73% | |
| Price/Sales | 5.46 |
| Company | Last | Change |
|---|---|---|
| Alcobra Ltd | 7.43 | -1.59% |
| Medgenics Inc | 4.06 | -0.25% |
| Prana Biotechnology Ltd | 2.27 | -0.45% |
| Oragenics Inc | 2.75 | -3.51% |
| StemCells Inc | 1.85 | -1.07% |
Data is delayed by at least 15 min.